{
  "symbol": "BIIB",
  "date": "2025-10-05",
  "headlines": [
    {
      "date": "2025-10-02",
      "time": "00:42",
      "title": "3 Low-Volatility Stocks That Concern Us\n\n\n(StockStory)",
      "link": "/news/181889/3-low-volatility-stocks-that-concern-us"
    },
    {
      "date": "2025-10-01",
      "time": "20:16",
      "title": "Jefferies Initiates Coverage on Biogen Inc. (BIIB) with Buy Rating and $190 PT\n\n\n(Insider Monkey)  +10.09%",
      "link": "/news/181709/jefferies-initiates-coverage-on-biogen-inc-biib-with-buy-rating-and-190-pt"
    },
    {
      "date": "2025-10-05",
      "time": "07:04PM",
      "title": "Chart Master: A breakout could signal more upside for beaten-down pharma stocks\n\n\n(CNBC TV)",
      "link": "https://www.youtube.com/watch?v=vU4IoqAQ91Q"
    },
    {
      "date": "2025-10-05",
      "time": "04:55PM",
      "title": "Drug Stock Rally Helps Push Dow and S&P 500 to Records\n\n\n(The Wall Street Journal)",
      "link": "https://www.wsj.com/finance/stocks/global-stocks-markets-dow-news-10-01-2025-bf78f02f?mod=wsj_FV"
    },
    {
      "date": "2025-10-05",
      "time": "02:48PM",
      "title": "Pharma stocks are powering the Nasdaq Composite and S&P 500 higher in afternoon trading\n\n\n(MarketWatch)",
      "link": "https://www.marketwatch.com/livecoverage/stock-market-today-dow-sp500-nasdaq-lower-us-government-shutdown-dollar-falls-gold-up-adp-data/card/pharma-stocks-are-powering-the-nasdaq-composite-and-s-p-500-higher-in-afternoon-trading-gC4u1tQSEjut3RqUk2K2?mod=mw_FV"
    },
    {
      "date": "2025-09-30",
      "time": "19:08",
      "title": "Analyst Report: Ionis Pharmaceuticals, Inc.\n\n\n(Morningstar Research)",
      "link": "https://finance.yahoo.com/m/1325da0d-e687-3ed1-8654-11f4b63ea974/analyst-report%3A-ionis.html"
    },
    {
      "date": "2025-10-05",
      "time": "06:49AM",
      "title": "NMPA approves Eisai and Biogen for Leqembi IV maintenance dosing\n\n\n(Pharmaceutical Technology)",
      "link": "https://finance.yahoo.com/m/467202d2-ebed-3a1d-9853-2b45a80c083b/nmpa-approves-eisai-and.html"
    },
    {
      "date": "2025-09-28",
      "time": "19:30",
      "title": "\"LEQEMBI\" (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in China\n\n\n(GlobeNewswire)",
      "link": "/news/177807/leqembi-lecanemab-iv-maintenance-dosing-for-the-treatment-of-early-alzheimers-disease-approved-in-china"
    },
    {
      "date": "2025-10-05",
      "time": "04:24PM",
      "title": "Biogen Inc. (BIIB): A Bull Case Theory\n\n\n(Insider Monkey)",
      "link": "/news/177767/biogen-inc-biib-a-bull-case-theory"
    },
    {
      "date": "2025-09-27",
      "time": "00:59",
      "title": "Biogen (BIIB) Expands Neurology Pipeline With Alcyone Buyout, Stock Seen Undervalued\n\n\n(Insider Monkey)",
      "link": "/news/177457/biogen-biib-expands-neurology-pipeline-with-alcyone-buyout-stock-seen-undervalued"
    },
    {
      "date": "2025-09-26",
      "time": "10:32",
      "title": "LLY Gets EU Approval for Alzheimer's Drug & FDA Nod to Cancer Therapy\n\n\n(Zacks)",
      "link": "/news/177063/lly-gets-eu-approval-for-alzheimers-drug-fda-nod-to-cancer-therapy"
    },
    {
      "date": "2025-10-05",
      "time": "08:24AM",
      "title": "The Baltics: a region punching above its weight on the global life sciences stage\n\n\n(Medical Device Network)",
      "link": "https://finance.yahoo.com/m/cec967a3-bed0-3cfd-8c9a-f5af2d9d4183/the-baltics%3A-a-region.html"
    },
    {
      "date": "2025-09-25",
      "time": "09:38",
      "title": "Oracle initiated, Ulta Beauty upgraded: Wall Street's top analyst calls\n\n\n(The Fly)",
      "link": "https://finance.yahoo.com/news/oracle-initiated-ulta-beauty-upgraded-133846264.html"
    },
    {
      "date": "2025-09-24",
      "time": "12:49",
      "title": "Biogens high-dose Spinraza turned down by FDA due to CMC troubles\n\n\n(Pharmaceutical Technology)",
      "link": "https://finance.yahoo.com/m/ac99487a-6076-3b36-a38c-7a8a96f3fd07/biogen%E2%80%99s-high-dose-spinraza.html"
    },
    {
      "date": "2025-10-05",
      "time": "12:41PM",
      "title": "BIIB's sNDA for Higher Dose of SMA Drug Spinraza Gets FDA's CRL\n\n\n(Zacks)",
      "link": "/news/174943/biibs-snda-for-higher-dose-of-sma-drug-spinraza-gets-fdas-crl"
    },
    {
      "date": "2025-10-05",
      "time": "07:30AM",
      "title": "LEQEMBI (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Australia\n\n\n(GlobeNewswire)",
      "link": "/news/174363/leqembi-lecanemab-approved-for-the-treatment-of-alzheimers-disease-in-australia"
    },
    {
      "date": "2025-09-23",
      "time": "16:41",
      "title": "US FDA declines to approve higher dose of Biogen's genetic disorder drug\n\n\n(Reuters)",
      "link": "https://finance.yahoo.com/news/us-fda-declines-approve-higher-204108259.html"
    },
    {
      "date": "2025-10-05",
      "time": "04:30PM",
      "title": "Biogen Provides Regulatory Update on High Dose Regimen of Nusinersen\n\n\n(GlobeNewswire)",
      "link": "/news/173800/biogen-provides-regulatory-update-on-high-dose-regimen-of-nusinersen"
    },
    {
      "date": "2025-10-05",
      "time": "02:15PM",
      "title": "IONS' Rare Neurological Disease Drug Meets Late-Stage Study Goal\n\n\n(Zacks)",
      "link": "/news/173730/ions-rare-neurological-disease-drug-meets-late-stage-study-goal"
    },
    {
      "date": "2025-09-19",
      "time": "04:44",
      "title": "Biogen to acquire Alcyone Therapeutics for $85m\n\n\n(Pharmaceutical Business Review)",
      "link": "https://www.pharmaceutical-business-review.com/news/biogen-alcyone-85m/"
    },
    {
      "date": "2025-09-18",
      "time": "09:17",
      "title": "Biogen Gets EU Nod for First Postpartum Depression Drug\n\n\n(Zacks)",
      "link": "/news/169561/biogen-gets-eu-nod-for-first-postpartum-depression-drug"
    },
    {
      "date": "2025-10-05",
      "time": "07:40AM",
      "title": "Biogen to Acquire Alcyone Therapeutics, Expanding Drug Delivery Solution Portfolio for Key Product and Pipeline Candidates\n\n\n(GlobeNewswire)",
      "link": "/news/169323/biogen-to-acquire-alcyone-therapeutics-expanding-drug-delivery-solution-portfolio-for-key-product-and-pipeline-candidates"
    },
    {
      "date": "2025-10-05",
      "time": "07:30AM",
      "title": "Biogens Zurzuvae approved as first postpartum depression drug in Europe\n\n\n(Pharmaceutical Technology)",
      "link": "https://finance.yahoo.com/m/d8dbc8c7-f5f2-36fd-8c1e-46a0fc0576f4/biogen%E2%80%99s-zurzuvae-approved-as.html"
    },
    {
      "date": "2025-10-05",
      "time": "07:07AM",
      "title": "Biogen to buy startup Alcyone, eyeing easier delivery of RNA drugs\n\n\n(BioPharma Dive)",
      "link": "https://finance.yahoo.com/m/a42626cc-c799-3d81-960c-ca966f939c55/biogen-to-buy-startup.html"
    },
    {
      "date": "2025-09-17",
      "time": "16:30",
      "title": "Biogen Receives European Commission Approval for ZURZUVAE (zuranolone), the First and Only Treatment Approved for Women with Postpartum Depression in Europe\n\n\n(GlobeNewswire)",
      "link": "/news/168928/biogen-receives-european-commission-approval-for-zurzuvae-zuranolone-the-first-and-only-treatment-approved-for-women-with-postpartum-depression-in-europe"
    },
    {
      "date": "2025-09-16",
      "time": "23:31",
      "title": "Firing on All Cylinders: Biogen (NASDAQ:BIIB) Q2 Earnings Lead the Way\n\n\n(StockStory)",
      "link": "/news/168094/firing-on-all-cylinders-biogen-nasdaq-biib-q2-earnings-lead-the-way"
    },
    {
      "date": "2025-10-05",
      "time": "02:58PM",
      "title": "Canaccord Genuity Reiterates a Buy on Biogen (BIIB)\n\n\n(Insider Monkey)",
      "link": "/news/167776/canaccord-genuity-reiterates-a-buy-on-biogen-biib"
    },
    {
      "date": "2025-09-15",
      "time": "09:03",
      "title": "H.C. Wainwright Affirms Biogen Inc. (BIIB) Buy Rating on Lupus Franchise Prospects\n\n\n(Insider Monkey)",
      "link": "/news/166030/hc-wainwright-affirms-biogen-inc-biib-buy-rating-on-lupus-franchise-prospects"
    },
    {
      "date": "2025-09-12",
      "time": "13:56",
      "title": "Is Biogen Stock Underperforming the Nasdaq?\n\n\n(Barchart)",
      "link": "https://finance.yahoo.com/m/cc345f4d-d9cc-3e32-baa5-97abf006849c/is-biogen-stock.html"
    },
    {
      "date": "2025-09-11",
      "time": "07:00",
      "title": "GE HealthCare inks Icometrix buyout to acquire brain MRI software\n\n\n(MedTech Dive)",
      "link": "https://finance.yahoo.com/m/3d88af3a-5e5d-3129-86a0-69e9317def62/ge-healthcare-inks-icometrix.html"
    },
    {
      "date": "2025-09-09",
      "time": "04:00",
      "title": "Can new Alzheimers tests help clear the way for the next generation of therapies?\n\n\n(Pharma Voice)",
      "link": "https://finance.yahoo.com/m/32a0664d-f6de-3c4e-9e4d-0806a60a0922/can-new-alzheimer%E2%80%99s-tests.html"
    },
    {
      "date": "2025-09-04",
      "time": "14:36",
      "title": "Biogen (BIIB) Stock Trades Down, Here Is Why\n\n\n(StockStory)",
      "link": "/news/158303/biogen-biib-stock-trades-down-here-is-why"
    },
    {
      "date": "2025-10-05",
      "time": "09:17AM",
      "title": "Will AbbVie's Neuroscience Portfolio Continue to Aid Top-line Growth?\n\n\n(Zacks)",
      "link": "/news/157934/will-abbvies-neuroscience-portfolio-continue-to-aid-top-line-growth"
    },
    {
      "date": "2025-09-03",
      "time": "10:47",
      "title": "IONS Hits 52-Week High on Tryngolza's Success in Lowering Triglyceride\n\n\n(Zacks)",
      "link": "/news/157020/ions-hits-52-week-high-on-tryngolzas-success-in-lowering-triglyceride"
    },
    {
      "date": "2025-09-02",
      "time": "21:05",
      "title": "Analyst Report: Ionis Pharmaceuticals, Inc.\n\n\n(Morningstar Research)  +5.60%",
      "link": "https://finance.yahoo.com/m/1d1bc07e-474d-31a7-9cc0-dae40b49947a/analyst-report%3A-ionis.html"
    },
    {
      "date": "2025-10-05",
      "time": "07:30PM",
      "title": "Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI IQLIK (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status\n\n\n(GlobeNewswire)",
      "link": "/news/156244/eisai-initiated-rolling-supplemental-biologics-license-application-to-the-us-fda-for-leqembi-iqlik-lecanemab-irmb-as-a-subcutaneous-starting-dose-for-the-treatment-of-early-alzheimers-disease-under-fast-track-status"
    },
    {
      "date": "2025-10-05",
      "time": "03:35PM",
      "title": "Biogen (BIIB) Stock Is Up, What You Need To Know\n\n\n(StockStory)",
      "link": "/news/155972/biogen-biib-stock-is-up-what-you-need-to-know"
    },
    {
      "date": "2025-10-05",
      "time": "10:23AM",
      "title": "Stock Market Today: Nasdaq, S&P 500 down over 1% after holiday weekend\n\n\n(TheStreet)",
      "link": "https://finance.yahoo.com/m/72d9fdc0-e7c1-3da0-9956-acd8c4ab589d/stock-market-today%3A-nasdaq%2C.html"
    },
    {
      "date": "2025-10-05",
      "time": "10:01AM",
      "title": "Eli Lilly's New Drugs Beyond Mounjaro and Zepbound Boost Sales\n\n\n(Zacks)",
      "link": "/news/155715/eli-lillys-new-drugs-beyond-mounjaro-and-zepbound-boost-sales"
    },
    {
      "date": "2025-10-05",
      "time": "09:51AM",
      "title": "Stock Market Today: Dow Dives 500 Points On Trump Tariff News; Nvidia, Palantir Sell Off (Live Coverage)\n\n\n(Investor's Business Daily)",
      "link": "https://finance.yahoo.com/m/3a3f2e58-f542-3b9d-bf15-4113ad1c2ca2/stock-market-today%3A-dow-dives.html"
    },
    {
      "date": "2025-10-05",
      "time": "09:48AM",
      "title": "These Stocks Are Moving the Most Today: Nvidia, PepsiCo, NIO, Constellation Brands, Biogen, and More\n\n\n(Barrons.com)",
      "link": "https://finance.yahoo.com/m/b47ba28a-cd53-3a01-ab0f-3a9ee464cb3e/these-stocks-are-moving-the.html"
    },
    {
      "date": "2025-10-05",
      "time": "08:20AM",
      "title": "Amgen to invest $600M in new US center; Sanofi drug for ITP approved\n\n\n(BioPharma Dive)",
      "link": "https://finance.yahoo.com/m/647688de-b04a-3193-acb4-442443f2a424/amgen-to-invest-%24600m-in-new.html"
    },
    {
      "date": "2025-10-05",
      "time": "07:00AM",
      "title": "Stoke Therapeutics and Biogen Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome\n\n\n(Business Wire)",
      "link": "https://www.businesswire.com/news/home/20250902984668/en"
    },
    {
      "date": "2025-10-05",
      "time": "07:00AM",
      "title": "Biogen and Stoke Therapeutics Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome\n\n\n(GlobeNewswire)",
      "link": "/news/155290/biogen-and-stoke-therapeutics-present-data-at-the-36th-international-epilepsy-congress-that-support-the-potential-for-zorevunersen-to-be-the-first-disease-modifying-medicine-for-dravet-syndrome"
    },
    {
      "date": "2025-10-05",
      "time": "03:30AM",
      "title": "Biogen Inc. (BIIB)'s Alzheimer's Drug Leqembi Wins EU Nod, Now Approved in 48 Countries\n\n\n(Insider Monkey)",
      "link": "/news/155043/biogen-inc-biibs-alzheimers-drug-leqembi-wins-eu-nod-now-approved-in-48-countries"
    },
    {
      "date": "2025-10-05",
      "time": "02:30AM",
      "title": "Startup Corsera Health aims to bring preventive heart medicine to the masses\n\n\n(BioPharma Dive)",
      "link": "https://finance.yahoo.com/m/a8c9adab-1442-31e7-b799-ddfb48e23948/startup-corsera-health-aims.html"
    },
    {
      "date": "2025-09-01",
      "time": "10:31",
      "title": "Biogen Secures FDA Nod for Subcutaneous Maintenance Dosing of Leqembi\n\n\n(Zacks)",
      "link": "/news/154786/biogen-secures-fda-nod-for-subcutaneous-maintenance-dosing-of-leqembi"
    },
    {
      "date": "2025-10-05",
      "time": "07:15AM",
      "title": "FDA approves Eisai and Biogen's Leqembi Iqlik BLA for early Alzheimer's\n\n\n(Pharmaceutical Business Review)",
      "link": "https://www.pharmaceutical-business-review.com/news/fda-eisai-biogens-leqembi-iqlik/"
    },
    {
      "date": "2025-08-29",
      "time": "17:06",
      "title": "FDA Approves Biogen, Eisai's Highly Anticipated Alzheimer's Treatment\n\n\n(Investor's Business Daily) \n\n +5.60%",
      "link": "https://www.investors.com/news/technology/biogen-eisai-under-the-skin-subcutaneous-leqembi-alzheimers-treatment?mod=IBD_FV"
    },
    {
      "date": "2025-10-05",
      "time": "05:00PM",
      "title": "FDA Approves LEQEMBI IQLIK (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease\n\n\n(PR Newswire)",
      "link": "/news/153978/fda-approves-leqembi-iqlik-lecanemab-irmb-subcutaneous-injection-for-maintenance-dosing-for-the-treatment-of-early-alzheimers-disease"
    },
    {
      "date": "2025-08-25",
      "time": "07:00",
      "title": "Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress\n\n\n(Business Wire)",
      "link": "https://www.businesswire.com/news/home/20250825375131/en"
    },
    {
      "date": "2025-10-05",
      "time": "07:00AM",
      "title": "Biogen and Stoke Therapeutics Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress\n\n\n(GlobeNewswire)",
      "link": "/news/148506/biogen-and-stoke-therapeutics-announce-presentations-of-clinical-data-from-studies-of-zorevunersen-for-the-potential-treatment-of-dravet-syndrome-at-the-36th-international-epilepsy-congress"
    },
    {
      "date": "2025-10-05",
      "time": "03:00AM",
      "title": "Austria and Germany to become the first markets in the European Union (EU) to launch LEQEMBI (lecanemab)\n\n\n(GlobeNewswire)",
      "link": "/news/148322/austria-and-germany-to-become-the-first-markets-in-the-european-union-eu-to-launch-leqembi-lecanemab"
    },
    {
      "date": "2025-08-21",
      "time": "17:49",
      "title": "Analyst Report: Ionis Pharmaceuticals, Inc.\n\n\n(Morningstar Research)",
      "link": "https://finance.yahoo.com/m/b18834ea-e57b-3a57-a376-94837b87a634/analyst-report%3A-ionis.html"
    },
    {
      "date": "2025-10-05",
      "time": "05:05AM",
      "title": "Biogen Stock: Analyst Estimates & Ratings\n\n\n(Barchart)",
      "link": "https://finance.yahoo.com/m/7538be5b-d017-3fbe-b6b7-32e24c4a9c10/biogen-stock%3A-analyst.html"
    },
    {
      "date": "2025-08-19",
      "time": "19:25",
      "title": "Analyst Report: Biogen Inc.\n\n\n(Morningstar Research)",
      "link": "https://finance.yahoo.com/m/e3a96360-be11-36e2-a4d7-1cd58175ecaf/analyst-report%3A-biogen-inc..html"
    },
    {
      "date": "2025-08-13",
      "time": "17:50",
      "title": "Biogen, Moderna, Align Technology, QuidelOrtho, and Masimo Shares Skyrocket, What You Need To Know\n\n\n(StockStory)",
      "link": "/news/139983/biogen-moderna-align-technology-quidelortho-and-masimo-shares-skyrocket-what-you-need-to-know"
    },
    {
      "date": "2025-08-12",
      "time": "23:48",
      "title": "BIIB Q2 Deep Dive: New Launches Offset Legacy Pressure, Pipeline Advancements Drive Guidance\n\n\n(StockStory)",
      "link": "/news/138280/biib-q2-deep-dive-new-launches-offset-legacy-pressure-pipeline-advancements-drive-guidance"
    },
    {
      "date": "2025-10-05",
      "time": "11:46PM",
      "title": "5 Revealing Analyst Questions From Biogen's Q2 Earnings Call\n\n\n(StockStory)",
      "link": "/news/138286/5-revealing-analyst-questions-from-biogens-q2-earnings-call"
    },
    {
      "date": "2025-10-05",
      "time": "10:30PM",
      "title": "[Latest] US Personalized Medicine Market Size/Share Worth USD 252.93 Billion by 2034 at a 17.32% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)\n\n\n(GlobeNewswire)",
      "link": "https://finance.yahoo.com/news/latest-us-personalized-medicine-market-023000015.html"
    },
    {
      "date": "2025-10-05",
      "time": "08:48AM",
      "title": "New .med Domain Names Surpass 40,000 Pre-Orders in July\n\n\n(PR Newswire)",
      "link": "https://finance.yahoo.com/news/med-domain-names-surpass-40-124800189.html"
    },
    {
      "date": "2025-10-05",
      "time": "08:18AM",
      "title": "DNLI Tops on Q2 Earnings, Expects Decree on Hunter Syndrome Drug in '26\n\n\n(Zacks)",
      "link": "/news/136698/dnli-tops-on-q2-earnings-expects-decree-on-hunter-syndrome-drug-in-26"
    },
    {
      "date": "2025-10-05",
      "time": "06:38AM",
      "title": "First patient dosed in Phase III trial of zorevunersen for Dravet syndrome\n\n\n(Clinical Trials Arena)",
      "link": "https://finance.yahoo.com/m/eeda0e34-7f66-3d9c-b061-ac2da5f89b15/first-patient-dosed-in-phase.html"
    },
    {
      "date": "2025-08-11",
      "time": "07:00",
      "title": "Stoke Therapeutics and Biogen Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome\n\n\n(Business Wire)",
      "link": "https://www.businesswire.com/news/home/20250811088079/en/"
    },
    {
      "date": "2025-10-05",
      "time": "07:00AM",
      "title": "Biogen and Stoke Therapeutics Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome\n\n\n(GlobeNewswire)",
      "link": "/news/134716/biogen-and-stoke-therapeutics-announce-first-patient-dosed-in-phase-3-emperor-study-of-zorevunersen-a-potential-disease-modifying-treatment-for-dravet-syndrome"
    },
    {
      "date": "2025-10-05",
      "time": "05:48AM",
      "title": "Chronic Inflammatory Demyelinating Polyneuropathy Market Report 2025 | Distribution Channel, Route of Administration, and Region Analysis and Forecast to 2035\n\n\n(GlobeNewswire)",
      "link": "https://finance.yahoo.com/news/chronic-inflammatory-demyelinating-polyneuropathy-market-094800268.html"
    },
    {
      "date": "2025-10-05",
      "time": "02:00AM",
      "title": "Gilead Stock Is Closing In on an All-Time High. The Case for More Upside.\n\n\n(Barrons.com)",
      "link": "https://finance.yahoo.com/m/21e99a61-5271-353e-b06d-95859eec457a/gilead-stock-is-closing-in-on.html"
    },
    {
      "date": "2025-10-05",
      "time": "02:00AM",
      "title": "Gilead Sciences Is Closing In on an All-Time High. The Case for More Upside.\n\n\n(Barrons.com)",
      "link": "https://www.barrons.com/articles/gilead-sciences-stock-price-gild-biotech-buy-cc8088b6?mod=bar_FV"
    },
    {
      "date": "2025-08-06",
      "time": "17:45",
      "title": "Analyst Report: Royalty Pharma plc\n\n\n(Morningstar Research)",
      "link": "https://finance.yahoo.com/m/73094d85-609d-337e-af32-c0099020a02d/analyst-report%3A-royalty.html"
    },
    {
      "date": "2025-08-04",
      "time": "16:05",
      "title": "Acadia Pharmaceuticals Appoints Scott Cenci as Chief Information and Data Officer\n\n\n(Business Wire)",
      "link": "https://finance.yahoo.com/news/acadia-pharmaceuticals-appoints-scott-cenci-200500187.html"
    },
    {
      "date": "2025-10-05",
      "time": "01:32PM",
      "title": "Biogen Inc. (BIIB): A Bull Case Theory\n\n\n(Insider Monkey)",
      "link": "/news/126779/biogen-inc-biib-a-bull-case-theory"
    },
    {
      "date": "2025-08-01",
      "time": "07:10",
      "title": "Regeneron cancer bispecific rejected again; Allogene discloses trial death\n\n\n(BioPharma Dive)",
      "link": "https://finance.yahoo.com/m/1997eb1b-2933-3051-9968-d6840fc9367b/regeneron-cancer-bispecific.html"
    },
    {
      "date": "2025-10-05",
      "time": "07:09AM",
      "title": "Supernus strengthens neuropsychiatric\u00a0portfolio with Sage Therapeutics\n\n\n(Pharmaceutical Technology)",
      "link": "https://finance.yahoo.com/m/0a48f4d2-0d03-389c-b1c3-6dd7cd89594a/supernus-strengthens.html"
    },
    {
      "date": "2025-10-05",
      "time": "04:00AM",
      "title": "Merck & Co. assembles an Alzheimers comeback with a next-gen precision focus\n\n\n(Pharma Voice)",
      "link": "https://finance.yahoo.com/m/c202e170-0ae8-352d-afce-8de279600a7c/merck-%26-co.-assembles-an.html"
    },
    {
      "date": "2025-10-05",
      "time": "01:44AM",
      "title": "Analyst Report: Biogen Inc.\n\n\n(Morningstar Research)",
      "link": "https://finance.yahoo.com/m/99c1c197-e4de-3ebf-b13f-fe53e60a0491/analyst-report%3A-biogen-inc..html"
    },
    {
      "date": "2025-07-31",
      "time": "11:49",
      "title": "Biogen Lifts Outlook As Rare Disease And Alzheimer's Drug Sales Accelerate\n\n\n(Benzinga)",
      "link": "https://finance.yahoo.com/news/biogen-lifts-outlook-rare-disease-154958884.html"
    },
    {
      "date": "2025-10-05",
      "time": "10:48AM",
      "title": "Biogen's Q2 Earnings & Sales Beat, 2025 Outlook Raised, Stock Up\n\n\n(Zacks)",
      "link": "/news/123093/biogens-q2-earnings-sales-beat-2025-outlook-raised-stock-up"
    },
    {
      "date": "2025-10-05",
      "time": "09:30AM",
      "title": "Biogen (BIIB) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates\n\n\n(Zacks)",
      "link": "/news/122768/biogen-biib-q2-earnings-taking-a-look-at-key-metrics-versus-estimates"
    },
    {
      "date": "2025-10-05",
      "time": "09:10AM",
      "title": "Ionis Beats on Q2 Earnings & Sales, Stock Up 5% on Raised '25 Outlook\n\n\n(Zacks)",
      "link": "/news/122696/ionis-beats-on-q2-earnings-sales-stock-up-5-on-raised-25-outlook"
    },
    {
      "date": "2025-10-05",
      "time": "07:27AM",
      "title": "Biogen Q2 Results Top Estimates; Boosts FY25 Outlook\n\n\n(RTT News)",
      "link": "https://www.rttnews.com/3560307/biogen-q2-results-top-estimates-boosts-fy25-outlook.aspx"
    },
    {
      "date": "2025-10-05",
      "time": "07:24AM",
      "title": "Biogen (NASDAQ:BIIB) Reports Bullish Q2\n\n\n(StockStory)",
      "link": "/news/122324/biogen-nasdaq-biib-reports-bullish-q2"
    },
    {
      "date": "2025-10-05",
      "time": "07:20AM",
      "title": "Biogen Inc. (BIIB) Surpasses Q2 Earnings and Revenue Estimates\n\n\n(Zacks)",
      "link": "/news/122429/biogen-inc-biib-surpasses-q2-earnings-and-revenue-estimates"
    },
    {
      "date": "2025-10-05",
      "time": "06:49AM",
      "title": "Biogen lifts full-year outlook amid Alzheimers drug strength, sending shares up\n\n\n(Investing.com)",
      "link": "https://finance.yahoo.com/news/biogen-lifts-full-outlook-amid-104934236.html"
    },
    {
      "date": "2025-10-05",
      "time": "06:23AM",
      "title": "Sales of Leqembi\u00ae totaled 23.1 billion yen in the second quarter 2025\n\n\n(PR Newswire)",
      "link": "https://finance.yahoo.com/news/sales-leqembi-totaled-23-1-102300766.html"
    },
    {
      "date": "2025-10-05",
      "time": "06:17AM",
      "title": "Biogen raises annual profit forecast on strong demand for rare disease drugs\n\n\n(Reuters)",
      "link": "https://finance.yahoo.com/news/biogen-raises-annual-profit-estimates-101724936.html"
    },
    {
      "date": "2025-10-05",
      "time": "05:43AM",
      "title": "Multiple Sclerosis Clinical Trials Market Landscape Report 2025 Featuring Biogen, Novartis, Sanofi, Merck, Teva, Bayer, Roche, Bristol-Myers Squibb, Laboratory Corp of America, IQVIA\n\n\n(GlobeNewswire)",
      "link": "https://finance.yahoo.com/news/multiple-sclerosis-clinical-trials-market-094300493.html"
    },
    {
      "date": "2025-10-05",
      "time": "12:16AM",
      "title": "Analyst Report: Ionis Pharmaceuticals, Inc.\n\n\n(Morningstar Research)",
      "link": "https://finance.yahoo.com/m/851f6c20-3cbe-397b-b153-5551bbe54998/analyst-report%3A-ionis.html"
    },
    {
      "date": "2025-07-30",
      "time": "16:05",
      "title": "Sage Therapeutics Announces Second Quarter 2025 Financial Results\n\n\n(Business Wire)",
      "link": "https://finance.yahoo.com/news/sage-therapeutics-announces-second-quarter-200500788.html"
    },
    {
      "date": "2025-10-05",
      "time": "11:00AM",
      "title": "Two-Year Real-World Study of LEQEMBI in the United States Presented at Alzheimer's Association International Conference (AAIC) 2025\n\n\n(GlobeNewswire)",
      "link": "/news/121105/two-year-real-world-study-of-leqembi-in-the-united-states-presented-at-alzheimers-association-international-conference-aaic-2025"
    },
    {
      "date": "2025-10-05",
      "time": "09:15AM",
      "title": "Biogen (BIIB) Q2 Earnings on the Horizon: Analysts' Insights on Key Performance Measures\n\n\n(Zacks)",
      "link": "/news/120867/biogen-biib-q2-earnings-on-the-horizon-analysts-insights-on-key-performance-measures"
    },
    {
      "date": "2025-10-05",
      "time": "09:00AM",
      "title": "New Data Presented at AAIC Demonstrates Investigational LEQEMBI\u00ae (lecanemab-irmb) 360 mg Subcutaneous Maintenance Dosing Could Offer a New Option for Ongoing Treatment of Early Alzheimer's Disease\n\n\n(PR Newswire)",
      "link": "https://finance.yahoo.com/news/data-presented-aaic-demonstrates-investigational-130000675.html"
    },
    {
      "date": "2025-10-05",
      "time": "08:07AM",
      "title": "Early Alzheimer's Patients Continue to Benefit from Four Years of LEQEMBI (lecanemab-irmb) Therapy New Clinical Data Presented at AAIC\n\n\n(PR Newswire)",
      "link": "/news/120526/early-alzheimers-patients-continue-to-benefit-from-four-years-of-leqembi-lecanemab-irmb-therapy-new-clinical-data-presented-at-aaic"
    },
    {
      "date": "2025-10-05",
      "time": "05:41AM",
      "title": "Eli Lilly eyes SoC status as Jaypirca proves superior to Imbruvica in CLL/SLL\n\n\n(Clinical Trials Arena)",
      "link": "https://finance.yahoo.com/m/df462f88-f0ba-3949-b1b2-0aaf54405a26/eli-lilly-eyes-soc-status-as.html"
    },
    {
      "date": "2025-07-29",
      "time": "23:06",
      "title": "Biogen Earnings: What To Look For From BIIB\n\n\n(StockStory)",
      "link": "/news/120164/biogen-earnings-what-to-look-for-from-biib"
    },
    {
      "date": "2025-10-05",
      "time": "01:39AM",
      "title": "Biogen (BIIB) to Invest $2 Billion in U.S. Expansion Amid Onshoring Push\n\n\n(Insider Monkey)",
      "link": "/news/118261/biogen-biib-to-invest-2-billion-in-us-expansion-amid-onshoring-push"
    },
    {
      "date": "2025-07-28",
      "time": "16:13",
      "title": "Biotech stocks dip as Trump administration mulls patent fee overhaul\n\n\n(Investing.com)",
      "link": "https://finance.yahoo.com/news/biotech-stocks-dip-trump-administration-201353984.html"
    },
    {
      "date": "2025-10-05",
      "time": "10:24AM",
      "title": "Biogen Gears Up to Report Q2 Earnings: Here's What to Expect\n\n\n(Zacks)",
      "link": "/news/117547/biogen-gears-up-to-report-q2-earnings-heres-what-to-expect"
    },
    {
      "date": "2025-10-05",
      "time": "10:00AM",
      "title": "BioMarin Pharmaceutical (BMRN) Reports Next Week: Wall Street Expects Earnings Growth\n\n\n(Zacks)",
      "link": "/news/117463/biomarin-pharmaceutical-bmrn-reports-next-week-wall-street-expects-earnings-growth"
    },
    {
      "date": "2025-07-25",
      "time": "07:20",
      "title": "ZURZUVAE (zuranolone) Receives Positive Opinion from CHMP for the Treatment of Women with Postpartum Depression\n\n\n(GlobeNewswire)",
      "link": "/news/115259/zurzuvae-zuranolone-receives-positive-opinion-from-chmp-for-the-treatment-of-women-with-postpartum-depression"
    },
    {
      "date": "2025-07-24",
      "time": "10:00",
      "title": "Analysts Estimate Biogen Inc. (BIIB) to Report a Decline in Earnings: What to Look Out for\n\n\n(Zacks)",
      "link": "/news/114246/analysts-estimate-biogen-inc-biib-to-report-a-decline-in-earnings-what-to-look-out-for"
    }
  ]
}